Influenza vaccines Vaccine safety data Main navigation COVID-19 vaccines Influenza vaccines 5 years and older (standard inactivated injectable vaccines) 50 years and older (adjuvanted or high-dose inactivated injectable vaccines) Mpox (monkeypox) vaccine National Immunisation Program schedule vaccines Nirsevimab RSV vaccines Vaccine safety in Australia AusVaxSafety summary reports AusVaxSafety commenced routine safety monitoring of 2026 seasonal influenza vaccines used in Australia across all ages in March 2026.The influenza vaccines in use in Australia in 2026 are:Standard inactivated (injectable) influenza vaccinesFlucelvax (individuals aged 6 months and older)Fluzone (individuals aged 6 months and older)Influvac (individuals aged 6 months and older)Vaxigrip (individuals aged 6 months and older)Adjuvanted or high-dose inactivated (injectable) influenza vaccines Fluad (individuals aged 50 years and older)Fluzone High-Dose (individuals aged 60 years and over)Intranasal live attenuated (nasal spray) influenza vaccine FluMist (individuals aged 2 years to less than 18 years)AusVaxSafety collects vaccine safety data using vaccine safety surveys sent to influenza vaccine recipients in the days following their vaccination. Latest influenza vaccine safety dataClick on the tiles below to view 2026 AusVaxSafety influenza vaccine safety data for specific age and population groups. Note: Additional age, population groups and vaccine types will be added below once enough data are collected for meaningful analysis. Influenza vaccine safety data – 5 years and older (standard inactivated injectable vaccines) View the latest safety data here Influenza vaccine safety data – 50 years and older (adjuvanted or high-dose inactivated injectable vaccines) View the latest safety data here Vaccine safety data Main navigation COVID-19 vaccines Influenza vaccines 5 years and older (standard inactivated injectable vaccines) 50 years and older (adjuvanted or high-dose inactivated injectable vaccines) Mpox (monkeypox) vaccine National Immunisation Program schedule vaccines Nirsevimab RSV vaccines Vaccine safety in Australia AusVaxSafety summary reports News & events All news & events 02 April 2026 | News AusVaxSafety begins surveillance of 2026 influenza vaccines, including new nasal spray option 05 March 2026 | News New LP.8.1 COVID-19 vaccines well tolerated, new AusVaxSafety data show 14 July 2025 | News Fewer adverse events reported following NIP pneumococcal vaccine change 03 June 2025 | News New AusVaxSafety data confirms Abrysvo RSV vaccine is well tolerated during pregnancy; adverse events comparable to other maternal vaccinations